2024 美国食品及药物管理局批准的精神药物：综述

IF 3.8 4区医学 Q1 PSYCHIATRY

Asian journal of psychiatry Pub Date : 2024-09-17 DOI:10.1016/j.ajp.2024.104249

Ahmed Naguy, Nadyah Alayadhi, Ali Al-Tajali, Victoria Ozidu

引用次数: 0

摘要

截至 2024 年 8 月，（美国）FDA 已批准了许多精神药物上市，它们可能会为精神药物治疗带来创新的火花。在此，我们将为忙碌的临床医生提供最新信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

2024 FDA-approved psychotropic medications: A conspectus

As of August 2024, (US) FDA has granted approval for a number of psychotropic drugs on market that might usher an innovative sparkle in psychopharmacotherapy. This is a recap to update busy clinicians.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Asian journal of psychiatry Medicine-Psychiatry and Mental Health

CiteScore

12.70

自引率

5.30%

发文量

297

审稿时长

35 days

期刊介绍： The Asian Journal of Psychiatry serves as a comprehensive resource for psychiatrists, mental health clinicians, neurologists, physicians, mental health students, and policymakers. Its goal is to facilitate the exchange of research findings and clinical practices between Asia and the global community. The journal focuses on psychiatric research relevant to Asia, covering preclinical, clinical, service system, and policy development topics. It also highlights the socio-cultural diversity of the region in relation to mental health.